Myostatin and sarcopenia: opportunities and challenges - a mini-review.
The progressive loss of skeletal muscle mass, strength and/or function with advancing age, termed sarcopenia, poses a major threat to independence and quality of life. Therefore, there is significant merit in better understanding the biology of sarcopenia and developing therapeutic interventions to prevent, slow or reverse its progression. Since the discovery of myostatin, a potent negative regulator of growth that is highly enriched in skeletal muscle, there has been great interest in it as a potential mediator of sarcopenia as well as a therapeutic target. The complex biology of myostatin, the promise of myostatin inhibition as an effective means to counter sarcopenia, and the challenges facing its clinical translation are reviewed herein.
Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, Minn., USA.
Thomas A
TA
White
Nathan K
NK
LeBrasseur
D000368:Aged; D000375:Aging / Q000473:pathology / Q000502:physiology; D000818:Animals; D006801:Humans; D051379:Mice; D018482:Muscle, Skeletal / Q000473:pathology / Q000503:physiopathology; D055435:Myostatin / Q000037:antagonists & inhibitors / Q000502:physiology*; D055948:Sarcopenia / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D015398:Signal Transduction
C525911:MSTN protein, human; D055435:Myostatin